New Advances in Melanoma
Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metas...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (148 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545107804498 |
---|---|
ctrlnum |
(CKB)5680000000037626 (oapen)https://directory.doabooks.org/handle/20.500.12854/81094 (EXLCZ)995680000000037626 |
collection |
bib_alma |
record_format |
marc |
spelling |
Larribère, Lionel edt New Advances in Melanoma Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (148 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed. English Public health & preventive medicine bicssc melanoma targeted therapies BRAF druggable mutations real-time PCR NGS assay immune escape microRNA transporter associated with antigen processing incidence population-based study epidemiology Spain skin cancer single-cell transcriptome sequencing treatment response pseudotime analysis treatment ubiquitination miRNAs embryogenesis melanoblasts melanoblast NF1 transcriptome RNAseq Trp-1 metastasis animal models lung mice 3-0365-3453-9 3-0365-3454-7 Larribère, Lionel oth |
language |
English |
format |
eBook |
author2 |
Larribère, Lionel |
author_facet |
Larribère, Lionel |
author2_variant |
l l ll |
author2_role |
Sonstige |
title |
New Advances in Melanoma |
spellingShingle |
New Advances in Melanoma |
title_full |
New Advances in Melanoma |
title_fullStr |
New Advances in Melanoma |
title_full_unstemmed |
New Advances in Melanoma |
title_auth |
New Advances in Melanoma |
title_new |
New Advances in Melanoma |
title_sort |
new advances in melanoma |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (148 p.) |
isbn |
3-0365-3453-9 3-0365-3454-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT larriberelionel newadvancesinmelanoma |
status_str |
n |
ids_txt_mv |
(CKB)5680000000037626 (oapen)https://directory.doabooks.org/handle/20.500.12854/81094 (EXLCZ)995680000000037626 |
carrierType_str_mv |
cr |
is_hierarchy_title |
New Advances in Melanoma |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796652002257666048 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03187nam-a2200661z--4500</leader><controlfield tag="001">993545107804498</controlfield><controlfield tag="005">20231214133440.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202205s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000037626</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/81094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000037626</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Larribère, Lionel</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Advances in Melanoma</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (148 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public health & preventive medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRAF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">druggable mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">real-time PCR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NGS assay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune escape</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transporter associated with antigen processing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">incidence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">population-based study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidemiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Spain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">skin cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">single-cell transcriptome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pseudotime analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ubiquitination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNAs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">embryogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoblasts</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoblast</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NF1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNAseq</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Trp-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mice</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3453-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3454-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larribère, Lionel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:54:21 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-05-14 21:41:54 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337804900004498&Force_direct=true</subfield><subfield code="Z">5337804900004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337804900004498</subfield></datafield></record></collection> |